Literature DB >> 9785162

Perceived contraindications to thrombolytic treatment in acute myocardial infarction. A survey at a teaching hospital.

D S Wald1.   

Abstract

OBJECTIVE: To examine the use of thrombolytic treatment in acute myocardial infarction when faced with perceived contraindications to treatment and to explore the justification for withholding treatment in such clinical situations.
METHODS: Interview survey of all doctors responsible administering thrombolysis to patients with acute myocardial infarction at a teaching hospital in the UK from March to May 1997.
RESULTS: 20 doctors were interviewed and asked whether they would give or withhold thrombolysis in a series of 19 clinical situations. These included patients presenting with both an acute myocardial infarction and one of the following associated conditions: a confirmed gastrointestinal haemorrhage, a suspected gastrointestinal haemorrhage, a peptic ulcer, an abdominal aortic aneurysm, a recent cerebrovascular accident, a known intracranial aneurysm, a known intracranial tumour, a recent dental extraction, recent surgery, severe hypertension, proliferative diabetic retinopathy, a history of bleeding diathesis, coma, recent cardiopulmonary resuscitation, pregnancy, menstruation, and a recent central venous puncture. In all but one of the clinical situations (definite current gastrointestinal haemorrhage) there was wide variation in response as to what constitutes a contraindication to thrombolytic treatment. Overall, a substantial proportion of doctors (35%-95%) would withhold treatment on account of any one of these clinical histories.
CONCLUSION: Clinicians may be withholding thrombolysis in acute myocardial infarction on account of perceived contraindications for which there is little or no evidence of increased haemorrhagic risk. An effective treatment for acute myocardial infarction is probably being underused.

Entities:  

Mesh:

Year:  1998        PMID: 9785162      PMCID: PMC1343175          DOI: 10.1136/emj.15.5.329

Source DB:  PubMed          Journal:  J Accid Emerg Med        ISSN: 1351-0622


  11 in total

1.  Is menstruation a contraindication to thrombolytic therapy?

Authors:  C R Conti
Journal:  Clin Cardiol       Date:  1992-09       Impact factor: 2.882

2.  Wide variation in the use of thrombolytic therapy among junior doctors in south and central Scotland.

Authors:  S Hood; D Birnie; J L Curzio; W S Hillis
Journal:  Health Bull (Edinb)       Date:  1996-03

3.  Safety of thrombolysis in association with cardiopulmonary resuscitation.

Authors:  S J Cross; H S Lee; J M Rawles; K Jennings
Journal:  BMJ       Date:  1991-11-16

4.  Is thrombolytic therapy safe during active menstruation?

Authors:  Y F Sekyema; R F Baltazar
Journal:  J Emerg Med       Date:  1995 May-Jun       Impact factor: 1.484

Review 5.  Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction.

Authors:  R Collins; R Peto; C Baigent; P Sleight
Journal:  N Engl J Med       Date:  1997-03-20       Impact factor: 91.245

6.  Thrombolytic treatment for myocardial infarction: an examination of practice in 39 United Kingdom hospitals. Myocardial Infarction Audit Group.

Authors:  J S Birkhead
Journal:  Heart       Date:  1997-07       Impact factor: 5.994

7.  Use of thrombolysis for acute myocardial infarction in the presence of diabetic retinopathy in the UK, and associated ocular haemorrhagic complications.

Authors:  E R Higgs; V J Parfitt; B A Harney; M Hartog
Journal:  Diabet Med       Date:  1995-05       Impact factor: 4.359

8.  Thrombolytic therapy in patients requiring cardiopulmonary resuscitation.

Authors:  A N Tenaglia; R M Califf; R J Candela; D J Kereiakes; E Berrios; S Y Young; R S Stack; E J Topol
Journal:  Am J Cardiol       Date:  1991-10-15       Impact factor: 2.778

9.  Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial.

Authors:  J M Gore; M Sloan; T R Price; A M Randall; E Bovill; D Collen; S Forman; G L Knatterud; G Sopko; M L Terrin
Journal:  Circulation       Date:  1991-02       Impact factor: 29.690

10.  Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.

Authors:  F Van de Werf; A E Arnold
Journal:  BMJ       Date:  1988-11-26
View more
  4 in total

1.  Safe use of thrombolysis in acute myocardial infarction.

Authors:  J Edhouse
Journal:  J Accid Emerg Med       Date:  1999-03

2.  Improving the management of acute myocardial infarction.

Authors:  Mark W Savage; Kevin S Channer
Journal:  BMJ       Date:  2002-11-23

3.  Suspected myocardial infarction and left bundle branch block: electrocardiographic indicators of acute ischaemia.

Authors:  J A Edhouse; M Sakr; J Angus; F P Morris
Journal:  J Accid Emerg Med       Date:  1999-09

4.  Intravenous thrombolysis in acute ischaemic stroke: from trial exclusion criteria to clinical contraindications. An international Delphi study.

Authors:  Maaike Dirks; Louis W Niessen; Peter J Koudstaal; Cees L Franke; Robert J van Oostenbrugge; Diederik W J Dippel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-01       Impact factor: 10.154

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.